Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Amortization (2020 - 2022)

Mereo BioPharma has reported Amortization over the past 3 years, most recently at $72.9 million for Q4 2022.

  • Quarterly Amortization fell 45.57% to $72.9 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $72.9 million through Dec 2022, down 45.57% year-over-year, with the annual reading at $72.9 million for FY2022, 45.57% down from the prior year.
  • Amortization was $72.9 million for Q4 2022 at Mereo BioPharma, down from $103.0 million in the prior quarter.
  • Over five years, Amortization peaked at $168.2 million in Q2 2021 and troughed at $72.9 million in Q4 2022.
  • The 3-year median for Amortization is $103.0 million (2022), against an average of $113.9 million.
  • Year-over-year, Amortization soared 46.2% in 2021 and then tumbled 45.57% in 2022.
  • A 3-year view of Amortization shows it stood at $91.6 million in 2020, then soared by 46.2% to $133.9 million in 2021, then tumbled by 45.57% to $72.9 million in 2022.
  • Per Business Quant, the three most recent readings for MREO's Amortization are $72.9 million (Q4 2022), $103.0 million (Q2 2022), and $133.9 million (Q4 2021).